A new wave of metabolic disease drugs beyond GLP-1 agonists is emerging to address the unmet needs of patients.
Discover what makes North Carolina’s Research Triangle Park’s life sciences and biotech ecosystem so successful.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback